HealthDay on MSN1d
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax wit ...
Kiromic says Deltacel-01 trial patient reaches progression-free survival
Kiromic BioPharma (KRBP) reported continued efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its ...
Cure Today4d
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 ...
MedPage Today3d
No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer
Opens in a new tab or window Palbociclib plus endocrine therapy did not improve overall survival in premenopausal patients with metastatic breast cancer. The regimen did improve progression-free ...
The American Journal of Managed Care5d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Cure Today2d
Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...
The American Journal of Managed Care4d
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected ...